Previous 10 | Next 10 |
Compugen to Present Data Update on COM701 Phase 1 Clinical Trial at the American Society of Clinical Oncology 2021 Annual Meeting PR Newswire HOLON, Israel, April 29, 2021 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy co...
Compugen (CGEN) announces preclinical data highlighting the potential of COM902, an anti-TIGIT therapeutic antibody, to enhance anti-tumor immune responses.COM902 binds specifically to TIGIT and disrupts the binding of TIGIT with PVR, the cognate ligand of TIGIT.Expression of TIGIT ...
Compugen Publishes Preclinical Data Demonstrating Therapeutic Potential of COM902 in Cancer Immunology, Immunotherapy Peer reviewed data demonstrate synergistic effect of anti-TIGIT antibody, COM902, with PVRIG and PD-1 blockade for the treatment of cancer Phase 1 trial of C...
Gainers: [[ANPC]] +32.0%. [[KLDO]] +3.4%. [[EBON]] +3.3%. [[VYGR]] +3.1%. [[RAIL]] +2.6%.Losers: [[CGEN]] -2.7%. [[RXRX]] -2.6%. [[CLPS]] -2.3%. [[LIZI]] -2.1%. [[VSTM]] -1.9%. For further details see: ANPC, KLDO, CGEN and CLPS among after-hours movers
ARK Invest's ARK Innovation ETF (ARKK) had a stellar 2020, delivering a 150% return and luring in more than $10 billion in fresh investor allocations during the year. Yet even while everything seemed to be coming up ARKK, a few analysts cautioned that the flood of inflows was, ironica...
Compugen Publishes Review on Biology and Potential Therapeutic Relevance of DNAM-1 axis in Cancer Immunotherapy The peer-reviewed article published in Cancer Discovery, a journal of the American Association for Cancer Research Anat Cohen-Dayag, Ph.D., President and CEO of Co...
Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference PR Newswire HOLON, Israel , March 8, 2021 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunot...
Compugen is an early-stage biotechnology company developing cancer immunotherapies from predictive computational discovery platforms. Compugen has an early-stage pipeline of three computationally-discovered therapeutic programs (COM701, COM902, and BAY 1905254) targeting immune checkp...
Image source: The Motley Fool. Compugen Ltd. (NASDAQ: CGEN) Q4 2020 Earnings Call Feb 26, 2021 , 8:30 p.m. ET Operator Continue reading For further details see: Compugen Ltd. (CGEN) Q4 2020 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN) Q4 2020 Earnings Conference Call February 25, 2021, 8:30 AM ET Company Participants Elana Holzman - Director, IR and Corporate Communications Anat Cohen-Dayag - President and CEO Henry Adewoye - SVP and CMO Ari Krashin - CFO and COO Eran Ophir - VP, Research and Dr...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...